Compare Rocket Lab USA Inc (RKLB) vs Royalty Pharma plc Class A Ordinary Shares (RPRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rocket Lab USA Inc vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? Rocket Lab USA Inc trades at $68.5 (market cap $43.74B), while Royalty Pharma plc Class A Ordinary Shares trades at $56.93 (market cap $25.27B). The key difference: Rocket Lab USA Inc is the larger of the two by market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while Rocket Lab USA Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Rocket Lab USA Inc for 29 Days and Royalty Pharma plc Class A Ordinary Shares for 1 Days on average.
| RKLB | RPRX | |
|---|---|---|
Market Cap | $43.74B | $25.27B |
Volume | 22,892,581 | 3,671,183 |
Sector | Industrials | Health |
52-Week High | $150.23 | $63.96 |
52-Week Low | $39.48 | $35.44 |
Typical Hold Time | 29 Days | 1 Days |
Enterprise Value | $41.57B | $32.50B |
Dividend Yield | — | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Rocket Lab (RKLB) trades at $68.35, down 4.96% in the last session, reflecting a bearish technical trend. The company's fundamentals show strong revenue growth, with 2026 revenue projected at $769 million, but it remains unprofitable with a net loss of -$165 million. Recent positive news includes securing its largest-ever commercial Electron launch deal with Synspective, boosting its backlog to over 100 missions. Analyst sentiment is predominantly bullish, with a consensus price target of $107.00.
The outlook for RKLB hinges on execution of its growing launch backlog and path to profitability. Investment opportunity lies in its leading position in small satellite launch services and expanding spacecraft business. Key risks include intense competition from SpaceX, high cash burn, and reliance on future Neutron rocket success. The stock offers high growth potential but carries significant execution and valuation risks.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Rocket Lab USA Inc
Rocket Lab USA, Inc. is an aerospace manufacturer and small-satellite launch service provider. The company specializes in developing rockets for orbital launch, including its flagship *Electron* vehicle, and is developing the next-generation, reusable *Neutron* rocket. Beyond launch services, Rocket Lab also offers satellite design, manufacturing, and spacecraft component solutions, positioning itself as an end-to-end provider for the space industry.
Read more on RKLB →About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →
